DSIP Capsules (Delta Sleep Inducing Peptide Capsules, delta sleep inducing peptide capsules) are oral formulations with DSIP (delta sleep inducing peptide) as the core ingredient, aimed at improving human health by regulating sleep cycles, alleviating stress responses, and potential clinical applications. DSIP, as a naturally occurring non peptide neuroregulatory substance, has become a research hotspot in the fields of neuroscience and medicine since its discovery in the 1970s due to its unique physiological effects and wide application prospects. Its physiological effects are significant, but traditional injection routes have problems such as inconvenient use and poor patient compliance. In addition, the oral bioavailability of DSIP is extremely low, which limits its application in clinical and healthcare fields. The development of DSIP capsules aims to improve the oral absorption rate of DSIP through formulation technology, thereby providing a more convenient and safe way to supplement DSIP.
Dsip COA
DSIP (Delta Sleep Inducing Peptide) is a short peptide consisting of 9 amino acids, initially isolated and extracted from rabbit brain homogenate, and later found to be widely distributed in the central nervous system and peripheral tissues of mammals. DSIP capsules, as oral formulations with DSIP as the core ingredient, aim to improve human health by regulating sleep cycles, alleviating stress reactions, and potential clinical applications.
Chemical properties and physiological basis of DSIP
Molecular structure and physicochemical properties
The molecular formula of DSIP is C35H48N10O15, with a molecular weight of approximately 849.8 g/mol. The amino acid sequence is Trp Ala Gly Gly Asp Ala Ser Gly Glu. Its molecular structure combines hydrophilic and hydrophobic regions, giving it a unique ability to penetrate biofilms. DSIP is stable at physiological pH and can tolerate enzymatic hydrolysis of gastric and pancreatic juices, but its oral bioavailability is extremely low (<1%), so traditional DSIP applications mainly rely on injection routes. The development of DSIP capsules aims to improve the oral absorption rate of DSIP through formulation technology improvements.
Natural distribution and synthetic pathways
DSIP is widely distributed in the hypothalamus, pituitary gland, adrenal gland, and peripheral tissues such as the gastrointestinal tract and pancreas. Its synthesis may involve the regulation of the hypothalamic pituitary adrenal axis (HPA axis), but the specific synthesis enzyme system and regulatory mechanism have not been fully elucidated. The DSIP in DSIP capsules may be obtained through chemical synthesis or bioengineering techniques to ensure their purity and activity.
Blood-brain barrier penetration ability
DSIP can efficiently penetrate the blood-brain barrier (BBB), and animal experiments have confirmed through radioactive labeling that injected DSIP can be quickly detected in brain tissue, and its concentration is positively correlated with plasma levels. This characteristic makes it one of the few exogenous peptide substances that can directly act on the central nervous system. DSIP capsules require formulation technology to protect DSIP from gastrointestinal enzymatic hydrolysis and promote its passage through the intestinal mucosa and blood-brain barrier, thereby exerting central nervous system regulatory effects.
Formulation technology of DSIP capsules
To improve the oral bioavailability of DSIP capsules, the following formulation techniques may be used:
Nanocarrier technology
Wrap DSIP in nanoparticles (such as liposomes and polymer nanoparticles) to protect it from gastrointestinal enzymatic hydrolysis and promote its passage through the intestinal mucosa. The particle size of nanoparticles is usually controlled between 100-200 nm to optimize their biological distribution and cellular uptake efficiency.
Micro pill technology
Make DSIP into microspheres to increase the contact area between drugs and intestinal mucosa, and improve absorption efficiency. The particle size of microspheres is usually controlled between 0.5-1.5 mm and can be prepared by extrusion rolling method or fluidized bed coating method.
Enteric coating technology
Wrap enteric coated materials (such as hydroxypropyl methylcellulose phthalate and cellulose acetate phthalate) around the outer layer of the capsule to release the drug in the intestine and prevent gastric acid damage. The thickness and composition of enteric coating need to be optimized to ensure drug release at specific pH values.
Penetration enhancer
Add penetration enhancers (such as bile salts and surfactants) to promote the penetration of DSIP through the intestinal mucosa. Common penetration enhancers include sodium dodecyl sulfate (SDS), polysorbate 80, etc., and their concentrations should be controlled within a safe range to avoid intestinal irritation.
The production process of DSIP capsules
The production process of DSIP capsules includes four main steps: raw material preparation, formulation preparation, quality testing, and packaging:
Raw material preparation
DSIP raw materials: DSIP is usually provided in the form of freeze-dried powder, and its purity must be ensured to be ≥ 98% (detected by HPLC), and it must meet the requirements of sterility and no pyrogen.
Accessories: including nanocarrier materials (such as liposome components), enteric coating materials, penetration enhancers, diluents (such as lactose, microcrystalline cellulose), lubricants (such as magnesium stearate), etc. All excipients must comply with pharmaceutical grade standards.
Solvent: The solvent used to dissolve DSIP and excipients (such as injection water, ethanol) must meet pharmacopoeia requirements and ensure sterility.
Preparation of formulations
Preparation of nanoparticles:
Liposome preparation: DSIP is encapsulated in lipid bilayers using thin film dispersion or reverse phase evaporation method. For example, phospholipids and cholesterol are dissolved in organic solvents (such as chloroform), evaporated to form a thin film, and then added to DSIP aqueous solution for hydration. Uniform liposomes are then prepared by ultrasound or extrusion methods.
Preparation of polymer nanoparticles: The emulsion solvent evaporation method is used to dissolve DSIP and polymers (such as polylactic acid hydroxyacetic acid copolymer, PLGA) in organic solvents. After emulsification, the solvent evaporates to form nanoparticles.
Preparation of microspheres:
Extrusion rolling method: Mix DSIP, diluent, and adhesive, extrude the strip through an extruder, and then prepare pellets through a rolling mechanism.
Fluidized bed coating method: DSIP pellets are placed in a fluidized bed and coated with enteric coating solution to form enteric coated pellets.
Capsule filling: Mix the prepared nanoparticles or microspheres with lubricant and fill them into hard or soft capsules. The filling process requires control of environmental humidity and temperature to avoid drug absorption or degradation.
quality inspection
Appearance inspection: The capsule should have a clean appearance, no cracks, discoloration, or foreign objects.
Content determination: HPLC method is used to determine the content of DSIP, ensuring that the content of DSIP in each capsule meets the labeled amount (such as 100 μ g/capsule).
Dissolution test: Simulate the gastrointestinal environment (such as hydrochloric acid solution with pH 1.2 and phosphate buffer solution with pH 6.8), determine the dissolution curve of DSIP, and ensure its release in the intestine.
Stability testing: Place the capsule under accelerated stability conditions (such as 40 ℃, 75% RH), regularly test the content and dissolution of DSIP, and evaluate its stability.
Microbial limit test: Ensure that the capsule meets the microbial limit standards (such as total bacterial count<1000 CFU/g, mold and yeast<100 CFU/g).
packaging
Inner packaging: Using aluminum foil PVC blister packaging or high-density polyethylene bottles to protect the capsules from light and humidity.
Outer packaging: Made of paper or plastic boxes, printed with product name, specifications, batch number, expiration date, and instructions for use.
Storage conditions: DSIP capsules usually need to be stored in a cool and dry place (such as 2-8 ℃) to maintain their stability.
Quality Control of DSIP Capsules
The quality control of DSIP capsules should comply with pharmacopoeia standards and relevant regulations, mainly including the following aspects:
Raw material quality control
DSIP raw materials: The supplier's COA (Certificate of Analysis) must be provided, and their purity, moisture, heavy metals, and microbial limits must be tested by themselves.
Auxiliary materials: Their characteristics, identification, content, and impurity limits need to be tested to ensure compliance with pharmaceutical grade standards.
Quality control of intermediate preparations
Nanoparticles or microspheres: their particle size distribution, Zeta potential, encapsulation efficiency (for nanoparticles), or roundness (for microspheres) need to be tested to ensure that they meet the formulation requirements.
Enteric coating: Its thickness, uniformity, and acid resistance (no drug release within 2 hours in hydrochloric acid solution with pH 1.2) need to be tested.
Finished product quality control
Content uniformity: The content determination method is used to ensure that the difference in DSIP content in each capsule is within the specified range (such as ± 10%).
Dissolution: It is necessary to meet the dissolution standard specified in the pharmacopoeia (such as Q value ≥ 80%) to ensure the bioavailability of the drug.
Stability: Long term stability data (such as 24 months) is required to prove the quality stability of the capsule during storage.
Hot Tags: dsip capsules, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale